Precision Medicine in Oncology /
Clasificación: | Libro Electrónico |
---|---|
Otros Autores: | , |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Wiley-Blackwell,
2020.
|
Edición: | 1st. |
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover
- Title Page
- Copyright Page
- Contents
- List of Contributors
- Preface
- List of Abbreviations
- Chapter 1 Genomic Strategies for Personalized Cancer Therapy
- 1.1 Introduction
- 1.1.1 Definition of Precision Medicine in Oncology
- 1.1.2 DNA and RNA Sequencing Techniques
- 1.2 Precision Medicine in Specific Tumors
- 1.2.1 Lung Cancer
- 1.2.1.1 Adenocarcinoma
- 1.2.1.2 Squamous Cell Carcinoma
- 1.2.1.3 Small-Cell Lung Carcinoma (SCLC)
- 1.2.1.4 Epidermal Growth Factor Receptor (EGFR) Mutations
- 1.2.1.5 Anaplastic Lymphoma Kinase (ALK)
- 1.2.1.6 BRAF, ROS1, MET
- 1.2.1.7 KRAS
- 1.2.1.8 Other: RET, NTRK
- 1.2.2 Head and Neck Cancers
- 1.2.2.1 HPV-Positive Cancers
- 1.2.2.2 HPV-Negative Cancers
- 1.2.2.3 Targeting the Epidermal Growth Factor Receptor (EGFR) Pathway
- 1.2.2.4 Thyroid Cancers
- 1.2.2.5 Other Targets
- 1.2.3 Hematological Malignancies
- 1.2.3.1 Lymphoma
- 1.2.3.2 Leukemia
- 1.2.3.3 Myelodysplastic Syndrome
- 1.2.4 Gynecologic Malignancies
- 1.2.4.1 Cervical
- 1.2.4.2 Uterine
- 1.2.4.3 Ovarian
- 1.2.5 Melanoma
- 1.2.6 Gastrointestinal Malignancies
- 1.2.6.1 Gastroesophageal Cancers
- 1.2.6.2 Colorectal Cancers
- 1.2.7 Breast Cancer
- 1.2.7.1 Basal-Like, or Triple Negative Breast Cancer
- 1.2.7.2 Luminal A/B, or Hormone Positive
- 1.2.7.3 HER2 Positive Breast Cancer
- 1.2.7.4 Immunotherapy
- 1.2.7.5 Germline Testing in Breast Cancer
- 1.2.7.6 Conclusion
- 1.2.8 Genitourinary Malignancies
- 1.2.8.1 Prostate Cancer
- 1.2.8.2 Renal Cell Cancer (RCC)
- 1.2.8.3 Urothelial Cancers
- 1.2.9 Pediatric Cancers
- 1.2.9.1 Introduction
- 1.2.9.2 Leukemia and Lymphoma
- 1.2.9.3 Central and Peripheral Nervous System Tumors
- 1.2.9.4 Bone and Soft Tissue Sarcomas
- 1.2.9.5 Other Embryonal Tumors
- 1.2.9.6 Conclusion
- 1.2.10 Cancers of Unknown Primary Origin
- 1.2.10.1 Diagnosis
- 1.2.10.2 Gene Expression Profiling
- 1.2.10.3 Mutational Testing with Next-Generation Sequencing (NGS)
- 1.2.10.4 Treatment
- 1.3 Biomarkers for Immunotherapy of Cancer
- 1.3.1 PD-L1
- 1.3.2 Soluble PD-L1 (sPD-L1)
- 1.3.3 Combined Positive Score (CPS)
- 1.3.4 Tumor Microenvironment
- 1.3.5 Tumor Mutational Burden (TMB)
- 1.3.6 Microsatellite Instability (MSI)
- 1.3.7 MMR Deficiency
- 1.3.8 Peripheral Blood Absolute Neutrophil Count/Absolute Lymphocyte Count
- 1.3.9 Microbiome
- 1.4 Clinical Trial Design in the Era of Precision Oncology
- 1.5 Ethical, Legal, and Social Issues of Precision Oncology
- 1.5.1 Ethical Issues
- 1.5.2 Legal Issues
- 1.5.3 Social Issues
- 1.6 Databases, Data Sharing, and Challenges of Precision Oncology
- References
- Chapter 2 Blood-Based Biomarkers for the Diagnosis and Prognosis of Cancer
- 2.3 Circulating Proteins as Biomarkers
- 2.4 Circulating Long Non-coding RNAs as Biomarkers
- 2.5 Circulating miRNAs as Biomarkers
- 2.6 Circulating Autoantibodies as Biomarkers
- 2.7 Circulating Tumor DNA as Biomarkers